Asad Kutup

Asad Kutup

Auto-generated profile, based on publicly available information

Asad Kutup

University Medical Center Hamburg-Eppendorf

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2015 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
PSPhillip Stahl
Phillip Stahl
CSCarsten Seeschaaf
Carsten Seeschaaf
PLPatrick Lebok
Patrick Lebok
AKAsad Kutup
Asad Kutup
MBMaximillian Bockhorn
Maximillian Bockhorn
AMAndreas H Marx
Andreas H Marx
Intra-tumor heterogeneity is a potential cause for failure of targeted therapy in gastric cancer, but the extent of heterogeneity of established (HER2) or potential (EGFR, CCND1) target genes and prognostic gene alterations (MYC) had not been systematically studied. To study heterogeneity of these genes in a large patient cohort, a heterogeneity tissue microarray was constructed containing 0.6 mm tissue cores from 9 different areas of the primary gastric cancers of 113 patients and matched lymph node metastases from 61 of these patients. Dual color fluorescence in-situ hybridization was performed to assess amplification of HER2, EGFR, CCND1 and MYC using established thresholds (ratio ≥ 2.0). Her2 immunohistochemistry (IHC) was performed in addition. Amplification was found in 17.4% of 109 interpretable cases for HER2, 6.4% for EGFR, 17.4% for CCND1, and 24.8% for MYC. HER2 amplification was strongly linked to protein overexpression by IHC in a spot-by-spot analysis (p < 0.0001). Intra-tumor heterogeneity was found in the primary tumors of 9 of 19 (47.3%) cancers with HER2, 8 of 17 (47.0%) cancers with CCND1, 5 of 7 (71.4%) cancers with EGFR, and 23 of 27 (85.2%) cancers with MYC amplification. Amplification heterogeneity was particularly frequent in case of low-level amplification (<10 gene copies). While the amplification status was often different between metastases, unequivocal intra-tumor heterogeneity was not found in individual metastases. The data of our study demonstrate that heterogeneity is common for biomarkers in gastric cancer. Given that both TMA tissue cores and clinical tumor biopsies analyze only a small fraction of the tumor bulk, it can be concluded that such heterogeneity may potentially limit treatment decisions based on the analysis of a single clinical cancer biopsy.

12 November 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KGKatharina Grupp
Katharina Grupp
BHBianca Hofmann
Bianca Hofmann
AKAsad Kutup
Asad Kutup
KBKai Bachmann
Kai Bachmann
DBDean Bogoevski
Dean Bogoevski
WWWaldemar Wilczak
Waldemar Wilczak
RBM3 expression has been suggested as prognostic marker in several cancer types. The purpose of this study was to assess the prevalence and clinical significance of altered RBM3 expression in esophageal cancer. RBM3 protein expression was measured by immunohistochemistry using tissue microarrays containing samples from 359 esophageal adenocarcinoma (EAC) and 254 esophageal squamous cell cancer (ESCC) patients with oncological follow-up data. While nuclear RBM3 expression was always high in benign esophageal epithelium, high RBM3 expression was only detectable in 66.4% of interpretable EACs and 59.3% of ESCCs. Decreased RBM3 expression was linked to a subset of EACs with advanced UICC stage and presence of distant metastasis (P = 0.0031 and P = 0.0024). In ESCC, decreased RBM3 expression was associated with advanced UICC stage, high tumor stage, and positive lymph node status (P = 0.0213, P = 0.0061, and P = 0.0192). However, RBM3 expression was largely unrelated to survival of patients with esophageal cancer (EAC: P = 0.212 and ESCC: P = 0.5992). In summary, the present study shows that decreased RBM3 expression is associated with unfavourable esophageal cancer phenotype, but not significantly linked to patient prognosis.

14 March 2007
Verified
Journal Article
Closed access
JKJussuf T Kaifi
Jussuf T Kaifi
GCGuel Cataldegirmen
Guel Cataldegirmen
RWRobin Wachowiak
Robin Wachowiak
PSPaulus G Schurr
Paulus G Schurr
HKHelge Kleinhans
Helge Kleinhans
JIJakob R Izbicki
Jakob R Izbicki

30 April 2000 in Gastroenterology
Verified
Journal Article
Closed access
AKAsad Kutup
Asad Kutup
SHStefan Benedikt Hosch
Stefan Benedikt Hosch
WKWolfram Trudo Knoefel
Wolfram Trudo Knoefel
PSPeter Scheunemann
Peter Scheunemann
MGMatthias Gundlach
Matthias Gundlach
JIJakob Robert Izbicki
Jakob Robert Izbicki

1 May 2011 in Gastroenterology
Verified
Journal Article
Closed access
DBDean Bogoevski
Dean Bogoevski
MRMatthias Reeh
Matthias Reeh
MBMaximilian Bockhorn
Maximilian Bockhorn
AKAlexandra M. Koenig
Alexandra M. Koenig
AKAsad R. Kutup
Asad R. Kutup
JIJakob Izbicki
Jakob Izbicki

17 September 2015
Verified
Book Chapter
Closed access
PDF file
MNMichael Nentwich
Michael Nentwich
AKAsad Kutup
Asad Kutup